TOPRA Calls for More Practical Approach to Regulatory Development
TOPRA has called on the regulatory community to develop a more consultative approach to legislation in light of a new poll revealing widespread concerns with the current channels of feedback.
TOPRA has called on the regulatory community to develop a more consultative approach to legislation in light of a new poll revealing widespread concerns with the current channels of feedback.
The new poll, which involved nearly 10% of TOPRA's membership, was published today to the TOPRA community. It highlights a series of worries within the current process of regulatory development.
When asked whether the practical implications of new legislation are sufficiently taken account of in the development phase, over 90 % of respondents believed that more could be done. This supports the motives behind TOPRA's continuing strategy of working closely with regulatory stakeholders to ensure regulation is effectively communicated
Over three quarters of respondents also felt that there is not an adequate system of feedback from the industry to those who draft the regulation - a problem that the Commission has spent the last six working hard to rectify.
Lynda Wight, TOPRA General Manager said:
"I think this confirms the view that there is still a lot of work for us to do to ensure that the views of those working at ground level are communicated to the regulatory agencies and policy-makers. Dr Philippe Brunet, formerly of the Commission, highlighted 'the communication channel between legislators and the grass-roots RA community' as a key area of development when he spoke at the TOPRA launch in April last year.
"We now need to work closely with our partners at the Commission and the regulatory agencies to ensure that we can consistently meet the expectations of the regulatory community."
TOPRA -- The Organisation for Professionals in Regulatory Affairs was launched on January 5th 2004. It is an international organisation with over 3,000 members across 52 countries.
TOPRA aims to provide its international membership with the highest quality education, information and career development services to ensure that the value and strategic contribution of regulatory affairs is universally recognised.
TOPRA conducted a popular poll of its membership in April 2005 asking a series of questions regarding the current state of the regulatory process.
Over 200 members responded to the poll.
91.7% of respondents said that they do not think the practical implications of new legislation are sufficiently taken account of when legislation is being drafted.
75.2% of respondents do not think there is an adequate system of feedback from industry to those who draft the legislation after implementation.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
